Dr Quentin Campbell-Hewson is the Chief Investigator for the ‘Eisai Hope Lenvatinib’ study that is currently recruiting patients in the UK. The trial is open to patients under the age of 18 years and is specifically for patients with osteosarcoma that has progressed after its initial treatment.
The trial involves a drug known as ‘Lenvatinib’, which is used either alone or alongside chemotherapy drugs Ifosfamide and Etoposide as a combination therapy. As with any clinical trial, there are entry requirements, known as ‘eligibility criteria’, and assessments that will need to take place before it is known if this trial is suitable for a patient.
Dr Campbell-Hewson got in touch with The Bone Cancer Research Trust to let us know about this trial and allow us to present this rare opportunity to osteosarcoma patients. He told us:
"As a doctor who has treated osteosarcoma patients for 15 years I am personally excited to have a new drug to use in combination chemotherapy. I am keen that any patients and families out there who have not had it offered know that it is a possible option."
The trial is now open at a number of European sites, but is specific to Newcastle, with Dr Campbell-Hewson, and Birmingham, with Dr Bruce Morland, here in the UK. Travel and accommodation arrangements can be made for suitable patients, so please do not hesitate to get in touch.
If you would like any more information on clinical trials in general, or would like to take part in this study, please contact us at The Bone Cancer Research Trust. We are happy to answer your queries and, if required, pass on your details to the lead of this trial, Dr Campbell-Hewson.